Jeff Martin
Stock Analyst at Roth Capital
(3.64)
# 821
Out of 4,964 analysts
61
Total ratings
63.79%
Success rate
18.72%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $54.39 | +36.05% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $19.68 | +37.20% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.23 | +18.20% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $9.30 | +50.54% | 8 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $229.12 | +6.93% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $6.10 | +47.54% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $48.54 | -7.29% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $20.65 | +45.28% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $42.43 | +1.34% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.38 | +417,291.30% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $54.39
Upside: +36.05%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $19.68
Upside: +37.20%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.23
Upside: +18.20%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $9.30
Upside: +50.54%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $229.12
Upside: +6.93%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $6.10
Upside: +47.54%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $48.54
Upside: -7.29%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $20.65
Upside: +45.28%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $42.43
Upside: +1.34%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.38
Upside: +417,291.30%